Comparison of the effect of subcutaneous progesterone and vaginal progesterone for luteal phase support
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
Objective: It was aimed to examine pregnancy rates by comparing the efficacy of subcutaneous and vaginal progesterone for luteal phase support in gonadotropin-induced IUI (intrauterine insemination) cycles. Methods: The study was conducted in Bezmialem Vakıf University Hospital between April 2022 and June 2022 as a prospective randomized controlled study. Patients who underwent IUI due to unexplained infertility, anovulation and mild male factor were included in the study. In total, 146 patients were randomized into two groups. From the first day after insemination, patients received intravaginal progesterone (LUTINUS® 100 mg vaginal tablet, Ferring GmbH Wittland/Kiel/Germany) once a day in group 1, subcutaneous progesterone in group 2 (PROLUTEX® 25 mg Injectable Solution, IBSA Group, Lugano, Switzerland) from the first day after insemination was given once a day. Pregnancy rates were recorded by performing a blood pregnancy test on the 15th day after the procedure. At the end of the study, betahCG positivity, biochemical pregnancy, clinical pregnancy and ongoing pregnancy rates of the patients were compared. Results: A total of 137 patients underwent IUI. As a result of the study, no statistically significant difference was observed between the groups in terms of demographic data, sperm parameters and cycle characteristics. When the pregnancy outcomes of the patients were examined, the rates of clinical pregnancy and ongoing pregnancy were higher in the group that received luteal phase support with vaginal progesterone compared to subcutaneous progesterone [RR 2.63; 95% CI, 1.26–5.49; p=0.011 and RR 2.87; 95% CI, 1.21–6.79; p=0.019]. There was no significant difference between the groups in terms of biochemical pregnancy and missed abortion rates [RR 0.63; 95% CI, 0.18–2.16; p=0.690 and RR 1.91; 95% CI, 0.36–10.1; p=0.718] Conclusion: Vaginal progesterone for luteal phase support in gonadotropin-induced IUI cycles provides a significantly higher clinical pregnancy and ongoing pregnancy rate than subcutaneous progesterone. Keywords: iui, luteal phase support, vaginal progesterone, subcutaneous progesterone
Author
Fulya Koç
How to Cite
Fulya Koç (Medical Specialty Thesis). Comparison of the effect of subcutaneous progesterone and vaginal progesterone for luteal phase support, 2022, Bezmialem Vakıf University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Bezmialem Vakıf University
- Assessment of micro RNA level of patients diagnosed with tuberous sclerosis(2016)
- Açık teknik septorinoplasti yapılan olgularda postoperatif bantlamanın ödeme etkisi(2015)
- 5-fluorourasile bağlı arteryel vazokonstrüksiyon etyolojisinde ürotensin-2'nin rolü(2017)
- Effect of postural training on musculoskeletal system, pain and quality of life in textile workers(2019)
- Effects of multimodal exercise program on motor and NON-motor symptoms of idiopathic parkinson patients and clinical correlation with ALPHA- synuclein level(2020)
- Comparing the efficacy of extracorporeal shock wave therapy, ultrasound and phonophoresis treatments in lateral epicondylitis: A randomized controlled trial(2022)
